title: TG4010: A therapeutic vaccine against MUC1 expressing tumors.
abstract: TG4010 is a therapeutic cancer vaccine based on a viral vector, a modified vaccinia of Ankara (MVA), expressing MUC1 as well as interleukine 2. Today the clinical development is focused on advanced non-small cell lung cancer in combination with first line chemotherapy. Potential biomarkers predictive of activity have been identified.
authors.affiliation: Transgene SA; Illkirch, France.
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Limacher
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Quoix